Birchview Capital, LP Infla Rx N.V. Transaction History
Birchview Capital, LP
- $117 Million
- Q4 2024
A detailed history of Birchview Capital, LP transactions in Infla Rx N.V. stock. As of the latest transaction made, Birchview Capital, LP holds 50,000 shares of IFRX stock, worth $69,500. This represents 0.11% of its overall portfolio holdings.
Number of Shares
50,000
Previous 50,000
-0.0%
Holding current value
$69,500
Previous $76,000
63.16%
% of portfolio
0.11%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding IFRX
# of Institutions
34Shares Held
13.6MCall Options Held
30.9KPut Options Held
2.1K-
Suvretta Capital Management, LLC New York, NY5.73MShares$7.97 Million0.59% of portfolio
-
683 Capital Management, LLC New York, NY2.07MShares$2.88 Million0.37% of portfolio
-
Morgan Stanley New York, NY2.04MShares$2.83 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL667KShares$926,9140.0% of portfolio
-
Raymond James Financial Inc St. Petersburg, FL638KShares$886,9470.0% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $61.4M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...